Understanding PMOS

If you’ve been living with irregular cycles, unexplained weight changes, hair thinning, skin breakouts, or fatigue that no one can quite explain, and someone once mentioned stress, but it never quite seemed to fit I want to introduce you to a name you might have heard of: PMOS (PCOS).

In May 2026, one of the most significant shifts in women’s health happened. The condition previously known as polycystic ovary syndrome (PCOS) was officially renamed polyendocrine metabolic ovarian syndrome or PMOS. The announcement was published in The Lancet on 12 May 2026, following a 14-year international consensus process led by Professor Helena Teede at Monash University, involving 56 medical societies, research organisations, and patient advocacy groups across six continents, and more than 22,000 responses from patients and health professionals worldwide.

That’s not a small update. That’s a reckoning.

And as a naturopath who works with women navigating hormonal and metabolic complexity every day, I think it matters a great deal not just semantically, but clinically.

Why ‘PCOS’ was always the wrong name

Here’s something that might surprise you: PCOS was never really about cysts. The ‘cysts’ visible on an ovarian ultrasound are not pathological cysts at all they are immature follicles, eggs that didn’t quite reach ovulation. They are a sign that something is disrupting the hormonal process, not a disease in themselves. True ovarian cysts are an entirely separate finding.

The name polycystic ovary syndrome implied the problem lived in the ovaries. It doesn’t. Research has consistently shown that PCOS now PMOS is a complex, multi-system condition involving the endocrine system, metabolism, insulin signalling, the adrenal glands, and in many cases, the immune and inflammatory pathways.

The old name led to real harm. Women were told they didn’t have PCOS because their ultrasound looked clear even when every other marker pointed directly to it. Others were given a diagnosis but not a meaningful explanation. Delayed diagnosis, fragmented care, stigma, and a treatment approach that often started and ended with the oral contraceptive pill: these have been the lived consequences of a name that didn’t tell the truth.

What PMOS actually means

The new name polyendocrine metabolic ovarian syndrome is more than a rebrand. Each word is doing real clinical work:

•       Polyendocrine means many hormonal systems are involved. Not just oestrogen and progesterone, but insulin, testosterone, DHEA-S, cortisol, thyroid hormones, and luteinising hormone. This is a condition of endocrine complexity.

•       Metabolic acknowledges that insulin resistance, blood sugar dysregulation, and cardiometabolic risk are often at the centre of what’s driving the hormonal picture. This is not incidental. It is fundamental.

•       Ovarian keeps the reproductive system in view because cycle irregularity, anovulation, and impacts on fertility are very real for many women with PMOS.

•       Syndrome reflects that this is a constellation of presentations, not a single, uniform disease. Which brings me to something important.

PMOS affects more than one in eight women worldwide. That is roughly 170 million people. It is the most common hormonal condition in women of reproductive age, and it has been chronically underdiagnosed, mismanaged, and misunderstood, in part because of a name that obscured what was actually happening.

The four subtypes of PMOS

This is where the clinical picture gets genuinely interesting, and where a root-cause approach becomes essential.

Within the PMOS umbrella, functional medicine and naturopathic practice identifies four common presentations, each with a different underlying driver. Knowing which one you’re dealing with changes everything about how you approach it.

1. Insulin-resistant PMOS

This is the most common subtype, present in roughly 70% of PMOS cases. Elevated insulin drives the ovaries to produce excess androgens (male hormones), disrupting ovulation and contributing to symptoms like irregular periods, weight gain particularly around the midsection, sugar cravings, brain fog, skin tags, and acanthosis nigricans (darkened skin patches at the neck or underarms).

This is also the subtype most likely to carry longer-term cardiometabolic risk if it goes unaddressed. Functional pathology is critical here: standard fasting glucose often looks fine, while fasting insulin, HOMA-IR, and a two-hour oral glucose tolerance test with insulin reveal what’s actually happening beneath the surface.

2. Adrenal PMOS

In adrenal PMOS, the excess androgens are coming from the adrenal glands rather than the ovaries specifically in the form of elevated DHEA-S. The ovaries may look entirely normal on ultrasound, and standard testosterone panels can miss this completely if DHEA-S isn’t tested.

Symptoms often flare during periods of high stress, burnout, or major life change. Women with this subtype frequently describe worsening of their hormonal symptoms during demanding seasons at work, relationship stress, or significant life events. The HPA axis the stress response system involving the hypothalamus, pituitary, and adrenal glands is central to understanding and addressing this presentation.

3. Inflammatory PMOS

Chronic low-grade inflammation disrupts ovarian function and hormone signalling. Women with inflammatory PMOS may present with a broader symptom picture that includes headaches, joint pain, unexplained fatigue, digestive symptoms, eczema or skin reactivity, and elevated inflammatory markers on pathology alongside the hormonal irregularities.

The gut-immune axis is often central to this subtype. Gut permeability, dysbiosis, and immune dysregulation can all feed into systemic inflammation that then disrupts endocrine function. This is why a thorough clinical picture not just hormone panels is essential.

4. Post-pill PMOS

Coming off hormonal contraception can trigger a rebound effect where the suppression of the hypothalamic-pituitary-ovarian axis resolves, and the body recalibrates sometimes in an exaggerated way. This can look like irregular or absent cycles, acne, hair loss, and elevated androgens in the months following cessation of the pill.

It’s important to note that in some cases, the pill was masking an underlying hormonal pattern that was always there. Coming off the pill didn’t cause PMOS; it revealed it. Distinguishing between a true post-pill rebound (which is usually temporary) and an unmasked underlying presentation requires careful clinical assessment over time.

Why functional pathology changes everything

Standard PMOS diagnosis relies on the Rotterdam criteria: two of three features must be present ovulatory dysfunction, elevated androgens, or polycystic ovarian morphology on ultrasound. This is a useful diagnostic framework, but it tells us what, not why.

Conventional pathology panels will often return within normal range even when a woman is clearly symptomatic. That’s not because nothing is wrong it’s because conventional reference ranges are built on population averages, not on what’s optimal for a functioning, thriving body.

Functional pathology looks at a broader and more targeted picture. Depending on a woman’s presentation, this might include:

•       Fasting insulin and HOMA-IR (insulin resistance markers rarely ordered by GPs)

•       A full androgen panel including DHEA-S, free and total testosterone, SHBG, and androstenedione

•       AMH (anti-Müllerian hormone) as a marker of ovarian reserve and follicular activity

•       A full thyroid panel including TSH, free T3, free T4, and thyroid antibodies

•       Inflammatory markers including CRP, ESR, and in some cases zonulin or calprotectin for gut permeability

•       Cortisol patterns via salivary testing to assess HPA axis function throughout the day

This isn’t about ordering everything. It’s about ordering the right things for this person, at this point in her hormonal story. The investigation should be led by the clinical picture, not by a checklist.

What the name change means for you right now

A three-year transition period is underway globally as clinical guidelines, medical education, and international disease classification systems update to reflect the new name. So, you may still see PCOS used by your GP, in pathology reports, and in older literature. That’s okay both terms refer to the same condition, and your existing diagnosis remains valid.

But what the name change signals is something the functional and naturopathic health world has always understood: this is not a condition that lives in your ovaries and is solved by the pill. It is a whole-body hormonal and metabolic condition that deserves a whole-body approach.

Knowing your subtype. Investigating your specific hormonal drivers. Using functional pathology to look beyond population-average reference ranges. Building a treatment plan that addresses the root cause, not just the visible symptoms. This is what meaningful care for PMOS actually looks like.

Ready to understand your hormonal picture at the root?

The PMOS Root Cause Reset is a structured program designed to identify your specific PMOS subtype, investigate your individual hormonal and metabolic drivers with functional pathology, and build a personalised treatment plan that actually addresses what’s going on not just what’s visible on a standard blood panel.

You can explore the program and book in via the link below. If you’d like to chat before committing, a complimentary Clarity Call is also available no obligation, just a conversation about where you are and whether this is the right fit.

→ Explore the PMOS Root Cause Reset